Despite headwinds for its multiple sclerosis (MS) franchise, Biogen (NASDAQ:BIIB) has been on a roll lately. The biotech won U.S. regulatory approval for spinal muscular atrophy (SMA) drug Spinraza in December. It also spun off its hemophilia business into a new company, Bioverativ, in February.
Biogen CEO Michel Vounatsos sat down at the Cowen & Company Annual Health Care Conference earlier this week to talk about his company’s future.
